Denali Advisors’s Celldex Therapeutics CLDX Stock Holding History

Denali Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,100	Closed	-$43K	–	386
2021 Q4	$43K	Buy	+1,100	New	+$47.9K	0.02%	261

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Denali Advisors's CLDX Position: Q1 2022 in Review

Denali Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 1,100 shares — an estimated $43K sold.

Denali Advisors first reported a position in CLDX in Q4 2021 and held it in 1 quarter. The position peaked at $43K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Denali Advisors reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
Denali Advisors sold 1,100 Celldex Therapeutics shares in Q1 2022, an estimated $43K.
Denali Advisors first reported a position in Celldex Therapeutics in Q4 2021 and held it in 1 quarter.
Denali Advisors's Celldex Therapeutics position peaked at $43K in Q4 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Denali Advisors's 13F filing for Q1 2022, filed 19 Apr 2022.